Patents by Inventor Werner Tegge

Werner Tegge has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11236059
    Abstract: The present invention is directed to novel natural product-derived ratjadone-based compounds useful as payloads (or toxins) in drug-conjugates constructs with cell target binding moieties (CTBM) and payload-linker compounds useful in connection with drug conjugates. The present invention further relates to new ratjadone compositions including the aforementioned payloads, payload-linkers and drug conjugates, and methods for using these payloads, payload-linkers and drug conjugates, to treat pathological conditions including cancer, inflammatory and infectious diseases.
    Type: Grant
    Filed: August 8, 2018
    Date of Patent: February 1, 2022
    Assignee: HELMHOLTZ-ZENTRUM FUER INFEKTIONSFORSCHUNG GMBH
    Inventors: Philipp Klahn, Mark Broenstrup, Verena Fetz, Wera Collisi, Katrin I Mohr, Stephan Huettel, Werner Tegge
  • Patent number: 10918733
    Abstract: The present invention relates to new lipopeptide- and lipoprotein molecules and lipopeptide- and lipoprotein-conjugates. In particular, the present invention relates to new lipopeptide- and lipoprotein molecules and lipopeptide- and lipoprotein-conjugates comprising a lipid-containing moiety representing an adjuvant moiety, a peptide or protein moiety whereby said peptide or protein moiety represents at least one antigenic structure, the antigen-moiety, and, optionally, a conjugate moiety, preferably a monodisperse polyethyleneglycol unit. Said compounds are particularly useful for therapeutic or prophylactic vaccination by mucosal or systemic administration, preferably mucosal and systemic vaccination. That is, the present invention relates in another aspect to pharmaceutical compositions comprising the compounds according to the present invention, in particular, said pharmaceutical compositions are vaccines.
    Type: Grant
    Filed: December 28, 2010
    Date of Patent: February 16, 2021
    Assignee: HELMHOLTZ-ZENTRUM FUER INFEKTIONSFORSCHUNG GMBH
    Inventors: Thomas Ebensen, Carlos Alberto Guzman, Michael Morr, Werner Tegge
  • Publication number: 20200239426
    Abstract: The present invention is directed to novel natural product-derived ratjadone-based compounds useful as payloads (or toxins) in drug-conjugates constructs with cell target binding moieties (CTBM) and payload-linker compounds useful in connection with drug conjugates. The present invention further relates to new ratjadone compositions including the aforementioned payloads, payload-linkers and drug conjugates, and methods for using these payloads, payload-linkers and drug conjugates, to treat pathological conditions including cancer, inflammatory and infectious diseases.
    Type: Application
    Filed: August 8, 2018
    Publication date: July 30, 2020
    Inventors: Philipp KLAHN, Mark BROENSTRUP, Verena FETZ, Wera COLLISI, Katrin I MOHR, Stephan HUETTEL, Werner TEGGE
  • Publication number: 20140329780
    Abstract: The present invention relates in the first aspect to the use of aurintricarboxylic acids, derivatives, oligo- or polymers or salts, for inhibiting adherence and colonisation of microorganisms, like bacteria, on surfaces, in particular for use in mammals. That is, it has been recognized that aurintricarboxylic acids and derivatives thereof are suitable for inhibiting adherence and colonisation of mucosa, in particular, nasal mucosa. In another aspect, the present invention relates to a method for preventing adherence of microorganisms, like bacteria, to a surface comprising the step of treating the surface with aurintricarboxylic acids, derivatives, or salts thereof. Finally, the present invention relates the use of aurintricarboxylic acids, derivatives or salts for preventing adherence of bacterial pathogens, in particular, of the genus Staphylococcus on surfaces.
    Type: Application
    Filed: October 12, 2012
    Publication date: November 6, 2014
    Inventors: Marina Steindorff, Werner Tegge
  • Publication number: 20130039939
    Abstract: The present invention relates to new lipopeptide- and lipoprotein molecules and lipopeptide- and lipoprotein-conjugates. In particular, the present invention relates to new lipopeptide- and lipoprotein molecules and lipopeptide- and lipoprotein-conjugates comprising a lipid-containing moiety representing an adjuvant moiety, a peptide or protein moiety whereby said peptide or protein moiety represents at least one antigenic structure, the antigen-moiety, and, optionally, a conjugate moiety, preferably a monodisperse polyethyleneglycol unit. Said compounds are particularly useful for therapeutic or prophylactic vaccination by mucosal or systemic administration, preferably mucosal and systemic vaccination. That is, the present invention relates in another aspect to pharmaceutical compositions comprising the compounds according to the present invention, in particular, said pharmaceutical compositions are vaccines.
    Type: Application
    Filed: December 12, 2009
    Publication date: February 14, 2013
    Inventors: Thomas Ebensen, Carlos Alberto Guzman, Michael Morr, Werner Tegge
  • Patent number: 6720161
    Abstract: The present invention refers to a method for attaching substrate molecules to gel matrices, characterized in that a substrate is covalently bound to a monomeric or oligomeric constitutional unit of a gel and the resultant product is polymerized. The present invention further refers to gels obtainable by this process.
    Type: Grant
    Filed: December 26, 2000
    Date of Patent: April 13, 2004
    Assignee: Gesellschaft fuer Biotechnologische Forschung mbH
    Inventors: Ronald Frank, Werner Tegge
  • Patent number: 6252042
    Abstract: Complexes, especially for the detection and separation of phosphoric-ester-containing compounds, are disclosed. The complexes according to the invention comprise at least one chelating agent, at least one central atom or central ion coordinated by the chelating agent(s), and at least one dye bonded to the chelating agent(s), etc.
    Type: Grant
    Filed: January 18, 2000
    Date of Patent: June 26, 2001
    Assignee: Gesellschaft fuer Biotechnologische Forschung mbH (GBF)
    Inventors: Werner Tegge, Rainer Gast, Joern Gloekler